Skip to content
DataLookout
Menu

NCT07078695

A Trial of SHR-1139 in Healthy Volunteers

StatusActive, Not Recruiting
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 11 words
    • Primary completion date changed from estimate of Sep 30, 2026 to Nov 9, 2026
    • Study completion pushed from Sep 30, 2026 to Jan 30, 2027
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v3
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 26, 2025 to Aug 19, 2025
    • Site details revised
    v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

PK profile of SHR-1139 after a single administration
Timeframe: Start of Treatment to end of study (Day 253)
PK profile of SHR-1139 after a single administration:
Timeframe: Start of Treatment to end of study (Day 253)
Immunogenicity profile of SHR-1139 after a single dose administration
Timeframe: Day 253

Secondary (1)

Safety and Tolerability Based on Incidence and Severity of Treatment Emergent Adverse Events

Arms and interventions

SHR-1139 dose level 1Experimental

Single dose of SHR-1139 given subcutaneously (dose level 1)

SHR-1139 dose level 2Experimental

Single dose of SHR-1139 given subcutaneously (dose level 2)

SHR-1139 dose level 3Experimental

Single dose of SHR-1139 given intravenously (dose level 3)

Drugs: SHR-1139 Injection

Sites

1 site in 1 country

  • LinearPerth, Western Australia, Australia